Revenue
2020
2021
2022
2023
2024
2025
Ovid Therapeutics Inc. (OVID)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $566,000 | $392,000 | $1.5M | $208.4M | $12.6M | — | — | — | — | — |
| Research & development | $25.6M | $36.8M | $28.6M | $24.6M | $46.9M | $63.4M | $42.2M | $33.8M | $50.0M | $9.6M | $6.6M |
| Operating expenses | $49.7M | $62.5M | $59.7M | $57.1M | $84.2M | $94.0M | $61.4M | $52.9M | $65.0M | $22.5M | $13.2M |
| Operating income | −$42.4M | −$61.9M | −$59.3M | −$55.5M | $124.2M | −$81.4M | −$61.4M | −$52.9M | −$65.0M | −$22.5M | −$13.2M |
| EBITDAderived | −$42.2M | −$61.3M | −$58.7M | −$55.0M | $124.4M | −$81.1M | −$61.2M | −$52.8M | −$64.9M | −$22.5M | −$13.2M |
| Net income | −$17.4M | −$26.4M | −$52.3M | −$54.2M | $122.8M | −$81.0M | −$60.5M | −$52.0M | −$64.8M | −$22.4M | −$13.2M |
| Basic EPSper diluted share | — | — | -$0.74 | -$0.77 | $1.78 | -$1.39 | — | -$2.11 | -$3.35 | -$2.28 | -$1.36 |
| Diluted EPSper diluted share | — | — | -$0.74 | -$0.77 | $1.76 | -$1.39 | — | -$2.11 | -$3.35 | -$2.28 | -$1.36 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 23, 2026Form 4 | ALEXANDER MARGARET A.President and CEO | SellCommon Stock | 11.7K | $1.45 | $16.9K | 61.8K |
| Feb 23, 2026Form 4 | Rona Jeffrey ACBFO | SellCommon Stock | 8.5K | $1.45 | $12.4K | 88.2K |
| Dec 11, 2025Form 4 | LEVIN JEREMY MCEO | BuySeries B Warrant (right to buy) · derivative | 35.5K | — | — | 35.5K |
| Dec 11, 2025Form 4 | LEVIN JEREMY MCEO | BuySeries A Warrant (right to buy) · derivative | 47.3K | — | — | 47.3K |
| Dec 11, 2025Form 4 | LEVIN JEREMY MCEO | BuySeries B Convertible Preferred Stock · derivative | 71 | — | — | 71 |